0.87
0.00%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Kindstar Globalgene Technology
Its shares trade on HKEX under the ticker 9960.HK. It has been listed since 16 July 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.09bn and a net loss of CN¥68.5m. At that date it held total assets of CN¥4.38bn and shareholders' equity of CN¥3.18bn.
Kindstar Globalgene Technology, Inc. is an investment holding company, which engages in the provision of clinical testing services. The company is headquartered in Wuhan, Hubei. The company went IPO on 2021-07-16. The firm operates nine segments. Hematology Testing segment includes testing services related to blood diseases. Genetic Diseases and Rare Diseases segment includes testing services from the rare disease. Infectious Diseases segment includes testing services from the infection department. Oncology segment includes testing related to oncology diseases. Neurology segment includes testing services related to neurological diseases undertaken by the Group. Maternity-related Diseases segment includes testing services related to maternity. COVID-19 Related Testing segment includes testing services related to COVID-19. Routine Testing segment conducts routine tests for the doctors’ daily diagnoses. The Others segment includes testing services for research and development (R&D) projects and others and miscellaneous services.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 16 Jul 2021
- Employees
- 3,214
- Website
- kindstar.com.cn ↗
Leadership
Pay as last reported
- Dr. Shiang HuangExecutive Chairman of the Board, Chief Executive Officer, Chief Medical Officer, since 2003CN¥794,000
- Ms. Haijie ChaiChief Financial Officer, Executive Director, Joint Company Secretary, since 2020CN¥611,000
- Mr. Zanbing TuChief Operating Officer, Executive Director, since 2020CN¥800,000
- Ms. Mei Yi LeeJoint Company Secretary
- Ms. Lu HuangNon-Executive DirectorCN¥63,000
- Mr. Zuie-Chin HuangNon-Executive Director
- Mr. Wei PengNon-Executive DirectorCN¥63,000
- Mr. Huaming GuNon-Executive Independent DirectorCN¥76,000
- Mr. Xinping XiaNon-Executive Independent DirectorCN¥81,000
- Dr. Shanglong YaoNon-Executive Independent DirectorCN¥66,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Kindstar Globalgene Technology Inc employs 3,214 full-time employees in Wuhan, China.
- The company operates nine distinct testing segments including Hematology and Oncology.
- Kindstar's IPO on 16 July 2021 provided significant capital for expansion.
Weaknesses
- The company's headquarters in Wuhan, Hubei, may limit access to global markets.
- Kindstar's business is heavily reliant on clinical testing services in China.
- The firm's nine segments require substantial operational coordination.
Opportunities
- Expanding into the growing Health Care sector in China offers significant growth potential.
- The increasing demand for genetic disease testing presents a key opportunity.
- Kindstar can leverage its nine segments to enter new markets in Asia.
Threats
- The global pandemic may disrupt clinical testing services and demand.
- Regulatory changes in China could impact the Health Care industry.
- Competition from other clinical testing providers in China poses a threat.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.